Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-β in combination with an analogue of 1α,25-dihydroxyvitamin-d3

Clinical and Experimental Immunology

Volumn 128, Issue 2, 2002, Pages 213-220

  Gysemans, C ^a   Van Etten, E ^a   Overbergh, L ^a   Verstuyf, A ^a   Waer, M ^a   Bouillon, R ^a   Mathieu, C ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b LEGENDO   (Belgium)

Author keywords

1,25 (OH)2D3; Autoimmune diabetes recurrence; Interferon ; Islet transplantation; Type 1 diabetes

Indexed keywords

CALCITRIOL DERIVATIVE; CYCLOSPORIN A; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; MESSENGER RNA; RECOMBINANT BETA INTERFERON; TX 527; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC OBESITY; FEMALE; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT SURVIVAL; MALE; MONOTHERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; RNA ANALYSIS; SURVIVAL TIME; TOXICITY TESTING; TREATMENT INDICATION; TREATMENT OUTCOME;

ALKYNES; ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; CHOLECALCIFEROL; COMBINED MODALITY THERAPY; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED NOD; RECURRENCE;

EID: 0036096735     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01825.x     Document Type: Article

References (39)

1. Transplantation treatment for diabetes
2. Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: Interleukin-2 and interferon gamma mRNA expression correlate with graft rejection and interleukin-10 with graft survival
3. Role of dendritic cells in the induction and maintenance of autoimmune diseases
4. Interferon beta in the cytokine network: An anti-inflammatory pathway
5. Interferon (IFN) β acts downstream of IFN-γ-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF-3-γ
6. Type I IFNs inhibit human dendritic-cell IL-12 production and Th1 cell development
7. Alpha-interferon inhibits the development of diabetes in NOD mice
8. 3 analog and cyclosporin
9. 3 as dose reducing agents for classical immunosuppressants
10. 1,25-Dihydroxyvitamin D3-a hormone with immunomodulatory properities
11. 1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation
12. Prevention of autoimmune diabetes in NOD mice by 1,25-dihyroxyvitamin D3
13. Beneficial effect of 1.25-dihydroxyvitamin D3 on cytokine-treated human pancreatic islets
14. Quantitative comparison of rapamycin and cyclosporin effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction
15. Preventive effects of azathioprine (AZA) on the onset of diabetes mellitus in NOD mice
16. The side-effects of cyclosporin-A and tacrolimus
17. Renal toxicity of long-term cyclosporin
18. Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporin in rats
19. New immunosuppressive drugs and diabetes
20. NOD mouse colonies around the world: Recent facts and figures
21. Islet xenograft destruction in hu-PBL-severe combined immunodeficient (SCID) mouse necessitates preactivation of human immune cells
22. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR
23. Subsets of macrophages and dendritic cells in nonobese diabetic mouse pancreatic inflammatory infiltrates: Correlation with the development of diabetes
24. Islet abnormalities associated with an early influx of dendritic cells and macrophages in NOD and NODscid mice
25. Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-β mRNA in the grafts
26. Interleukin-12 expression in islets correlates with beta-cell destruction in NOD mice
27. 3
28. Nuclear factor of activated T cells (NFAT) as molecular target for 1,25-dihydroxyvitamin D3-mediated effects
29. Vitamin D3: A transcriptional modulator of the interferon-γ gene
30. The mechanism of action of cyclosporin A and FK 506
31. Interleukin-4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in non-obese diabetic mice
32. Pancreatic expression of IL-4 abrogates insulitis and autoimmune diabetes in non-obese diabetic (NOD) mice
33. Mechanism underlying counterregulation of autoimmune diabetes by IL-4
34. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse
35. IL-4 triggers autoimmune diabetes by increasing self-antigen presentation within the pancreatic islets
36. Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate cytotoxic CD8+ T-cell responses
37. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells
38. The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes
39. Transgenic expression of interleukin-10 in the pancreas renders resistant mice susceptible to low dose streptozotocin-induced diabetes